1-(prop-2-ynyl)piperidin-3-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(prop-2-ynyl)piperidin-3-ol
• 英文别名: 1-(prop-2-yn-1-yl)piperidin-3-ol；1-prop-2-ynylpiperidin-3-ol
• 化学式: C₈H₁₃NO
• mdl: MFCD14645217
• 分子量: 139.197
• InChiKey: SIYJFRXEYQGHPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(prop-2-ynyl)piperidin-3-ol 在 bis-triphenylphosphine-palladium(II) chloride 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 copper(l) iodide 、 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 15.0h， 生成 2,4-difluoro-N-(5-(4-(3-(3-hydroxypiperidin-1-yl)prop-1-ynyl)quinolin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors

  摘要：

  A novel series of 4-alkynyl-quinoline derivatives were designed, synthesized and biologically evaluated for their PI3K alpha inhibitory activities and anti-proliferative effects against two cancer cell lines PC-3 and HCT-116. Most of them showed potent PI3K alpha inhibitory activities with IC50 values at low nanomolar level and good to excellent anti-proliferative effects against both cell lines. Among them, compound 15d, the most potent one, was selected for further biological evaluation. As a result, 15d displayed strong inhibitory activity against other class I PI3K isoforms (PI3K beta, PI3K gamma and PI3K delta) and mTOR with an acceptable kinase selectivity profile. Moreover, the western blot assay indicated that the phosphorylation of Akt, another downstream effector of PI3K, can be remarkably suppressed by 15d at cellular level. All these experimental results suggested that 15d is a potent PI3K/mTOR dual inhibitor and could serve as a promising lead compound for the development of anticancer agents. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.05.025
• 作为产物：
  描述：

  3-羟基哌啶 、 3-溴丙炔 在 caesium carbonate 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 24.0h， 以86%的产率得到1-(prop-2-ynyl)piperidin-3-ol
  参考文献：
  名称：

  N-烷基哌啶氨基甲酸酯可能作为抗阿兹海默症的药物。

  摘要：

  能够与涉及阿尔茨海默氏病（AD）发病机理的单个或多个靶标相互作用的化合物是潜在的抗阿尔茨海默氏病药物。为了开发新的抗阿尔茨海默病药物，我们设计，合成和评估了36种新型N-烷基哌啶氨基甲酸酯，以抑制胆碱酯酶[乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BChE）]和单胺氧化酶[单胺氧化酶A（ MAO-A和单胺氧化酶B（MAO-B）]。四种化合物很有希望：多种AChE（IC50 = 7.31μM），BChE（IC50 = 0.56μM）和MAO-B（IC50 = 26.1μM）抑制剂10，双重AChE（IC50 = 2.25μM）和BChE（IC50 = 0.81μM）抑制剂22，选择性BChE（IC50 = 0.06μM）抑制剂13和选择性MAO-B（IC50 = 0.18μM）抑制剂16。酶动力学实验的结果表明，尽管结构中存在氨基甲酸酯基团，化合物10、13和22是可逆且非时间依赖性的AChE

  DOI：

  10.1016/j.ejmech.2020.112282

文献信息

• Substituted bicyclic derivatives useful as anticancer agents
  申请人：——

  公开号：US20010034351A1

  公开（公告）日：2001-10-25

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R 1 , R 3 and R 4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及公式11的化合物及其药学上可接受的盐和溶剂化物，其中A、X、R1、R3和R4的定义如本文所述。本发明还涉及使用公式1的化合物治疗哺乳动物中的异常细胞生长的方法，并涉及含有公式1的化合物的治疗此类疾病的制药组合物。本发明还涉及制备公式1的化合物的方法。
• SUBSTITUTED BENZENE COMPOUNDS
  申请人：EPIZYME, INC.

  公开号：US20150284370A1

  公开（公告）日：2015-10-08

  The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及取代苯基化合物。本发明还涉及含有这些化合物的制药组合物，以及通过将这些化合物和制药组合物用于需要此类治疗的受试者来治疗癌症的方法。本发明还涉及将这些化合物用于研究或其他非治疗目的的用途。
• Substituted benzene compounds
  申请人：Epizyme, Inc.

  公开号：US10092572B2

  公开（公告）日：2018-10-09

  The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

  本发明涉及取代苯化合物。本发明还涉及含有这些化合物的药物组合物，以及通过向有需要的受试者施用这些化合物和药物组合物来治疗癌症的方法。本发明还涉及将这些化合物用于研究或其它非治疗目的。
• SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Pfizer Products Inc.

  公开号：EP1147093B1

  公开（公告）日：2007-04-11
• US6284764B1
  申请人：——

  公开号：US6284764B1

  公开（公告）日：2001-09-04